Aims There is a high prevalence of hypertension in the African population and it is known that vascular dysfunction (including nitric oxide (NO) bio-availability markers) play an important role in the development of cardiovascular diseases. Since very little is known regarding the role of markers of NO bio-availability in Africans, the aim of this study was to compare markers of NO bio-availability (namely L-arginine, L-citrulline, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)), ambulatory blood pressure (BP) and markers of end organ damage between African and Caucasian school teachers. Additionally, we also aimed to determine whether these markers of NO bio-availability are associated with ambulatory BP and markers of end organ damage in both ethnic groups. Methods The SABPA (Sympathetic activity and Ambulatory Blood Pressure in Africans) study was a cross-sectional study, including urbanised African (N=181) and Caucasian (N=209) men and women, between the ages of 25 and 65 years. Cardiovascular measurements included ambulatory blood pressure, pulse wave velocity (PWV), electrocardiographic Cornell product and carotid intima media thickness (cIMT). Anthropometric measurements included height, weight and waist circumference. Various bio-markers were analysed, including glucose, L-arginine, ADMA, SDMA, Lcitrulline, reactive oxygen species, albumin-to-creatinine ratio (ACR) and estimated creatinine clearance (eCCR). Characteristics of groups were compared with independent T-tests and Chi-square tests. Single and partial analyses were used to investigate associations between NO bioavailability markers with ambulatory BP measurements and markers of end organ damage. Analyses of covariance (ANCOVA) were used for comparison of variables between groups to determine significant differences, while adjusting for age, body mass index and antihypertensive medication. Forward stepwise multiple regression analyses were performed to determine if independent associations exist between ambulatory BP measurements or markers of end organ damage with either- L-arginine, L-citrulline, ADMA or SDMA as the main independent variable. Results and conclusion The Africans and Caucasians were of similar ages. However, the Africans had higher blood pressure therefore their cardiovascular profile was unfavourable compared to that of the Caucasians. The inhibitors of NO biosynthesis, ADMA and SDMA, were significantly lower in the Africans (p=0.046; p<0.001, respectively). However, the NO bio-availability markers, L-arginine and L-citrulline, were higher in the African compared to the Caucasian participants (all p values <0.05) regarded as significant. When performing unadjusted analyses, we found significant negative associations between eCCR and L-citrulline in all four subgroups: African men (r=-0.27; p=0.013), African women (r=-0.24; p=0.021), Caucasian men (r=-0.21; p=0.044) and Caucasian women (r=-0.28; p=0.003). The association of eCCR with L-citrulline was confirmed to be independent of confounders in all groups: African men (R2=0.46; β=-0.23; p=0.006), African women (R2=0.68; β= -0.12; p=0.046), Caucasian men (R2=0.62; β= -0.24; p<0.001) and Caucasian women (R2=0.72; β= -0.13; p=0.029). This implicates that renal function may be detrimentally affected by L-citrulline concentrations. In the Caucasian men and women negative correlations between eCCR and SDMA were found before adjustments (r=-0.33; p=0.003 and r=-0.26; p=0.006, respectively). This phenomenon was confirmed in the forward stepwise multiple regression analysis in Caucasian men (R2=0.75; β= -0.27; p<0.001) and women (R2=0.73; β= -0.21; p<0.001), while no associations were found in the Africans. This result is not unexpected, since SDMA can only be eliminated by the kidneys and is therefore an important risk marker for the early detection of renal dysfunction. In Caucasian men we found that ADMA correlated with ACR (r=0.36; p=0.001), night-time SBP (r=0.34; p=0.002) and night-time DBP (r=0.25; p=0.023) with single linear regression analyses. A similar trend was shown in African men with night-time SBP (r= 0.20; p=0.089) and night-time DBP (r= 0.21; p=0.078) respectively, but this association was absent in the Caucasian and African women. After adjustments for age and body mass index, the associations with ADMA, ACR and SBP in the Caucasian men remained. However, a negative association between eCCR and ADMA also became evident in the African men (r=- 0.24; p=0.025) and remained significant in the forward stepwise multiple regression analysis (R2=0.44; β= -0.18; p=0.034). It is, however, not clear why our results were gender specific, but we could speculate that the female sex hormones may play a part in protecting the vascular endothelium. Apart from the associations described above, there were no significant independent associations between the markers of the NO cycle (such as L-arginine) and PWV, cIMT, eCCR, ACR or Cornell product. In conclusion, although Africans presented a more vulnerable cardiovascular profile, we found a consistent negative association between renal function and L-citrulline in all participants, which has only been reported previously in patients with chronic renal disease. Additionally we found a gender-specific link between renal function and ADMA in African and Caucasian men. Our results may indicate that in the general population, markers of NO bioavailability may be associated with early changes in renal function, accompanying elevated blood pressure. / Thesis (MSc (Physiology))--North-West University, Potchefstroom Campus, 2013

Aims There is a high prevalence of hypertension in the African population and it is known that vascular dysfunction (including nitric oxide (NO) bio-availability markers) play an important role in the development of cardiovascular diseases. Since very little is known regarding the role of markers of NO bio-availability in Africans, the aim of this study was to compare markers of NO bio-availability (namely L-arginine, L-citrulline, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)), ambulatory blood pressure (BP) and markers of end organ damage between African and Caucasian school teachers. Additionally, we also aimed to determine whether these markers of NO bio-availability are associated with ambulatory BP and markers of end organ damage in both ethnic groups. Methods The SABPA (Sympathetic activity and Ambulatory Blood Pressure in Africans) study was a cross-sectional study, including urbanised African (N=181) and Caucasian (N=209) men and women, between the ages of 25 and 65 years. Cardiovascular measurements included ambulatory blood pressure, pulse wave velocity (PWV), electrocardiographic Cornell product and carotid intima media thickness (cIMT). Anthropometric measurements included height, weight and waist circumference. Various bio-markers were analysed, including glucose, L-arginine, ADMA, SDMA, Lcitrulline, reactive oxygen species, albumin-to-creatinine ratio (ACR) and estimated creatinine clearance (eCCR). Characteristics of groups were compared with independent T-tests and Chi-square tests. Single and partial analyses were used to investigate associations between NO bioavailability markers with ambulatory BP measurements and markers of end organ damage. Analyses of covariance (ANCOVA) were used for comparison of variables between groups to determine significant differences, while adjusting for age, body mass index and antihypertensive medication. Forward stepwise multiple regression analyses were performed to determine if independent associations exist between ambulatory BP measurements or markers of end organ damage with either- L-arginine, L-citrulline, ADMA or SDMA as the main independent variable. Results and conclusion The Africans and Caucasians were of similar ages. However, the Africans had higher blood pressure therefore their cardiovascular profile was unfavourable compared to that of the Caucasians. The inhibitors of NO biosynthesis, ADMA and SDMA, were significantly lower in the Africans (p=0.046; p<0.001, respectively). However, the NO bio-availability markers, L-arginine and L-citrulline, were higher in the African compared to the Caucasian participants (all p values <0.05) regarded as significant. When performing unadjusted analyses, we found significant negative associations between eCCR and L-citrulline in all four subgroups: African men (r=-0.27; p=0.013), African women (r=-0.24; p=0.021), Caucasian men (r=-0.21; p=0.044) and Caucasian women (r=-0.28; p=0.003). The association of eCCR with L-citrulline was confirmed to be independent of confounders in all groups: African men (R2=0.46; β=-0.23; p=0.006), African women (R2=0.68; β= -0.12; p=0.046), Caucasian men (R2=0.62; β= -0.24; p<0.001) and Caucasian women (R2=0.72; β= -0.13; p=0.029). This implicates that renal function may be detrimentally affected by L-citrulline concentrations. In the Caucasian men and women negative correlations between eCCR and SDMA were found before adjustments (r=-0.33; p=0.003 and r=-0.26; p=0.006, respectively). This phenomenon was confirmed in the forward stepwise multiple regression analysis in Caucasian men (R2=0.75; β= -0.27; p<0.001) and women (R2=0.73; β= -0.21; p<0.001), while no associations were found in the Africans. This result is not unexpected, since SDMA can only be eliminated by the kidneys and is therefore an important risk marker for the early detection of renal dysfunction. In Caucasian men we found that ADMA correlated with ACR (r=0.36; p=0.001), night-time SBP (r=0.34; p=0.002) and night-time DBP (r=0.25; p=0.023) with single linear regression analyses. A similar trend was shown in African men with night-time SBP (r= 0.20; p=0.089) and night-time DBP (r= 0.21; p=0.078) respectively, but this association was absent in the Caucasian and African women. After adjustments for age and body mass index, the associations with ADMA, ACR and SBP in the Caucasian men remained. However, a negative association between eCCR and ADMA also became evident in the African men (r=- 0.24; p=0.025) and remained significant in the forward stepwise multiple regression analysis (R2=0.44; β= -0.18; p=0.034). It is, however, not clear why our results were gender specific, but we could speculate that the female sex hormones may play a part in protecting the vascular endothelium. Apart from the associations described above, there were no significant independent associations between the markers of the NO cycle (such as L-arginine) and PWV, cIMT, eCCR, ACR or Cornell product. In conclusion, although Africans presented a more vulnerable cardiovascular profile, we found a consistent negative association between renal function and L-citrulline in all participants, which has only been reported previously in patients with chronic renal disease. Additionally we found a gender-specific link between renal function and ADMA in African and Caucasian men. Our results may indicate that in the general population, markers of NO bioavailability may be associated with early changes in renal function, accompanying elevated blood pressure. / Thesis (MSc (Physiology))--North-West University, Potchefstroom Campus, 2013

Protein arginine methylation is an essential post-translational modification catalyzed by protein arginine methyltransferases (PRMTs). Type I PRMTs transfer the methyl group from S-adenosyl-L-methionine (AdoMet) to the arginine residues and catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA). Type II PRMTs generate MMA and symmetric dimethylarginine (SDMA). PRMT-catalyzed methylation is involved in many biological processes and human diseases when dysregulated. As the predominant PRMT, PRMT1 catalyzes an estimated 85% of all protein arginine methylation in vivo. Nevertheless, the product specificity of PRMT1 remains poorly understood. A few articles have been published regarding the kinetic mechanism of PRMT1, yet with controversial conclusions. To gain more insights into the product specificity of PRMT1, we dissected the active site of PRMT1 and identified two conserved methionines (Met-48 and Met-155) significant for the enzymatic activity and the product specificity. These two methionines regulate the final product distribution between MMA and ADMA by differentially affecting the first and second methyl transfer step. Current data show that Met-48 also specifies ADMA formation from SDMA. To further understand the kinetic mechanism of PRMT1, we developed a double turnover experiments to conveniently assay the processivity of the two-step methyl transfer. Using the double turnover experiments, we observed that PRMT1-catalyzed dimethylation is semi-processive. The degree of processivity depends on the substrate sequences, which satisfies the controversy between the distributive or partially processive mechanisms previously reported. We are using transient kinetics and single turnover experiments to further investigate the mechanism of PRMT1. Interestingly, during these studies, we found that PRMT1 may incur oxidative damage and the histidine affinity tag influences the protein characteristics of PRMT1. These studies have given important insights into the product specificity and kinetic mechanism of PRMT1, and provided a strong foundation for future studies on PRMT1.

Protein arginine methyltransferases (PRMTs) posttranslationally modify protein arginine residues. Type I PRMTs catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA) via methyl group transfer from S-adenosyl methionine onto protein arginine residues. Type II PRMTs generate MMA and symmetric dimethylarginine. PRMT-methylation affects many biological processes. Although PRMTs are vital to normal development and function, PRMT-methylation is also linked to cardiovascular disease, stroke, multiple sclerosis, and cancer. Thus far, nine human PRMT isoforms have been identified with orthologues present in yeast, plants, and fish. PRMT1 predominates, performing an estimated 85% of all protein arginine methylation in vivo. Yet, the substrate specificity and catalytic mechanism of PRMT1 remain poorly understood. Most PRMT1 substrates are methylated within repeating `RGG' and glycine-arginine rich motifs. However, PRMT1 also methylates a single arginine on histone-H4 that is not embedded in a glycine-arginine motif, indicating that PRMT1 protein substrates are not limited to proteins with `RGG' sequences. In order to determine if PRMT1 displays broader substrate selectivity, I first developed a continuous spectrophotometric assay to measure AdoMet-dependent methyltransferase activity. Using this assay and a focused peptide library based on a sequence derived from the in vivo PRMT1 substrate fibrillarin, we observed that PRMT1 demonstrates amino acid sequence selectivity in peptide and protein substrates. PRMT1 methylated eleven substrate motifs that went beyond the `RGG' and glycine-arginine rich paradigm, suggesting that the methyl arginine proteome may be larger and more diverse than previously thought. PRMT1 methylates multiple arginine residues within the same protein to form protein-associated MMA and ADMA. Interestingly, ADMA is the dominant biological product formed and is a predictor of mortality and cardiovascular disease. To understand why PRMT1 preferentially forms ADMA in vivo, we began to 1) probe the mechanism of ADMA formation and 2) examine the catalytic role of certain active site residues and their involvement in ADMA formation. We found that PRMT1 dissociatively methylated several peptide substrates and preferred to methylate mono-methylated substrates over their non-methylated counterparts. Methylation of a multiple arginine-containing substrate was systematic (not random), a phenomenon that may be important biologically. All in all, our data help explain how PRMT1 generates ADMA in vivo.

Ce projet de thèse avait pour objet d’étudier la régulation de la biodisponibilité du monoxyde d’azote (NO) à travers la supplémentation en nitrate (NO3-) chez l’homme, et la perfusion d’ADMA chez l’animal. Nous avons essayé de déterminer les répercussions de la modulation de la biodisponibilité du NO sur la perfusion musculaire à l’exercice, et l’effet de l’aptitude aérobie sur cette modulation. Dans notre méta-analyse, nous avons rapporté une diminution de la consommation d’oxygène (V̇O2) lors d’exercices d’intensité modérée à élevée, avec une amélioration de la tolérance à l’exercice sans réduction du V̇O2 chez les sujets présentant une pathologie. Dans une seconde étude, aucune amélioration de la tolérance à l’effort n’a été observée chez des athlètes [consommation maximale d’oxygène (V̇O2max) > 65 mL.min-1.kg-1] au cours d’un exercice intermittent d’intensité supramaximale après une supplémentation en NO3- et sans modification au niveau du V̇O2 et de la perfusion musculaire. Une troisième étude montre que l’aptitude aérobie et l’apport en O2 aux muscles, dépendante de la perfusion musculaire, ne sont pas associés à la concentration plasmatique d’ADMA chez des sujets jeunes et sains. Enfin, notre quatrième étude ne rapporte pas d’effet de la perfusion de l’ADMA sur la perfusion musculaire au cours d’un exercice de course chez des rats. En conclusion, la supplémentation en NO3- peut contribuer à une amélioration de la performance à travers une réduction du coût en O2 pour des exercices sous-maximaux. Cependant, les sujets entraînés en endurance avec une aptitude aérobie élevée ne présentent ni d’effet ergogénique, ni d’amélioration de la perfusion musculaire à la suite d’une supplémentation en NO3- lors d’exercices intermittents supramaximaux, contrairement aux sujets modérément entraînés. En outre, l’ADMA, en tant inhibiteur de la synthèse du NO, ne semble pas jouer un rôle dans la régulation du débit sanguin et de l’apport en O2 aux muscles actifs, en l’absence de conditions pathologiques. / We aimed to determine whether dietary nitrate (NO3-) supplementation and ADMA modulate NO bioavailability and muscle blood flow during exercise. The second purpose was to establish whether aerobic fitness alters the effects of dietary NO3- supplementation and ADMA on muscle blood flow during exercise. In our meta-analysis, we found that dietary NO3- supplementation decreases V̇O2 during exercise performed in the moderate and heavy intensity domains in healthy subjects, and enhances exercise tolerance in subjects with chronic diseases, but no change in V̇O2. Our second study showed that dietary NO3- supplementation did not increase the number of repetitions completed during supramaximal intensity intermittent exercise in endurance athletes with high aerobic fitness (V̇O2max > 65 mL.kg-1.min-1), and did not increase muscle blood volume. In the third study, aerobic fitness is not related to muscle O2 delivery and plasma ADMA concentrations in young male subjects with a wide range of aerobic fitness level. In the fourth study, increased plasma ADMA levels did not decrease muscle blood flow during low-treadmill running exercise in healthy rats. In conclusion, dietary NO3- supplementation could contribute to an improved tolerance to exercise by reducing O2 cost during exercises at submaximal intensities. However, endurance-trained athletes with high V̇O2max level do not benefit from the effects of dietary NO3- supplementation on exercise performance and muscle blood flow as reported in moderately trained subjects. Moreover, ADMA did not regulate muscle blood flow and O2 delivery during exercise in conditions free from cardiovascular and metabolic diseases in humans and in the rat with pharmacological-induced increase in plasma ADMA levels.

No description available.

Intaktes Endothel und die ausreichende Funktion der endothelialen NO-Synthase (eNOS) sind Voraussetzungen für gesunde Gefäße. Eine endotheliale Dysfunktion besteht bei Patienten mit kardiovaskulären Risikofaktoren bzw. manifester koronarer Herzerkrankung (KHK). Endotheliale Vorläuferzellen (EPC) sind ein wichtiger Faktor für die Aufrechterhaltung der Homöostase des Endothels. Im klinischen Teil der vorliegenden Arbeit konnte gezeigt werden, dass diese Vorläuferzellen mit zunehmender Schwere der KHK in geringerem Maß im Blut zirkulieren. Die Anzahl der EPC war bei Patienten mit einer koronaren 3-Gefäßerkrankung um 77 % geringer, die Anzahl der kolonie-bildenden Einheiten (CFUs) um 50,3%, jeweils verglichen mit Patienten ohne KHK. Bei diesen Patienten konnte ebenfalls gezeigt werden, dass sich die Konzentration des endogenen eNOS-Inhibitors asymmetrisches Dimethylarginin (ADMA) im Plasma mit zunehmender Schwere der KHK erhöhte (0,47 ± 0,02 μmol/l bei fehlender KHK gegenüber 0,58 ± 0,02 μmol/l bei koronarer 3-Gefäßerkrankung). ADMA ist über eine Hemmung der eNOS an der Entstehung und Aufrechterhaltung einer endothelialen Dysfunktion beteiligt. Über diesen Weg wird vermutlich auch die Funktion der EPC erheblich eingeschränkt. Dies konnten wir anhand der In­vitro­Versuche mit EPC gesunder Spender zeigen. Dabei reduzierte sich unter ADMA-Einfluß die Anzahl der EPC in Kultur, die Anzahl und Größe der CFUs und ihre Funktion bzw. ihre Fähigkeit, sich in gefäßähnliche Strukturen zu integrieren. Eine gleichzeitige Gabe des HMG-CoA-Reduktase-Inhibitors Rosuvastatin wirkte in all diesen In-vitro-Versuchen der hemmenden Wirkung von ADMA entgegen. Die vorliegende Arbeit zeigt erstmals eine inverse Korrelation zwischen ADMA-Spiegeln und der Anzahl und Funktion der EPC. Der negative Einfluss auf EPCs ist vermutlich ein wichtiger Mechanismus, über den ADMA der Entstehung und dem Fortschreiten kardiovaskulärer Erkrankungen Vorschub leistet. / Endothelial progenitor cells play a pivotal role in regeneration of injured endothelium, thereby limiting the formation of atherosclerotic lesions. Reduced numbers of EPCs may affect progression of coronary artery disease. Regulation of EPC mobilization and function is mediated in part by nitric oxide (NO). Endogenous inhibitors of NO synthases, such as ADMA, contribute to endothelial dysfunction and injury. We tested the hypothesis that asymmetric dimethylarginine (ADMA) may be an endogenous inhibitor of endothelial progenitor cells (EPCs). We used flow cytometry and in vitro assays to investigate the relationship between EPC number and function with ADMA plasma levels in patients with stable angina. The plasma concentration of ADMA was related to the severity of coronary artery disease and correlated inversely with the number of circulating CD34+/CD133+ progenitor cells (r = -0.69; p < 0.0001) and endothelial colony forming units (CFUs) (r = -0.75; p < 0.0001). Adjusting for all patient characteristics, we confirmed these findings in multivariate regression analyses. In vitro differentiation of EPCs was repressed by ADMA in a concentration-dependent manner. Compared with untreated cells, ADMA reduced EPC incorporation into endothelial tube-like structures to 27 +/- 11% (p < 0.001). Asymmetric dimethylarginine repressed the formation of CFUs from cultured peripheral blood mononuclear cells to 35 +/- 7% (p < 0.001). Asymmetric dimethylarginine decreased endothelial nitric oxide synthase activity in EPCs to 64 +/- 6% (p < 0.05) when compared with controls. Co-incubation with the hydroxymethyl glutaryl coenzyme A reductase inhibitor rosuvastatin abolished the detrimental effects of ADMA. CONCLUSIONS: Asymmetric dimethylarginine is an endogenous inhibitor of mobilization, differentiation, and function of EPCs. This contributes to the cardiovascular risk in patients with high ADMA levels and may explain low numbers and function of EPCs in patients with coronary artery disease.

Nitric oxide synthases (NOS) are responsible for the production of nitric oxide (NO), an essential cell-signaling molecule, in mammals. There are three isoforms of NOS with widely different tissue distribution. The overproduction of NO is marked in many human disease states and cancers, however due to the similarities of the enzyme isoforms, targeting NOS for inhibition has proven challenging. Endogenously, the methylated arginines, N[superscript ω]-monomethyl-L-arginine (NMMA) and asymmetric N[superscript ω], N[superscript ω]-dimethyl-L-arginine (ADMA), inhibit NOS. N[superscript ω], N[superscript ω]-Dimethylarginine dimethylaminohydrolase (DDAH1) metabolizes these methylated arginines and thus relieves NOS inhibition. The role of DDAH1 in the regulation of diseases such as cancer and septic shock is still being elucidated. It is thought that targeting DDAH1 for inhibition rather than NOS may circumvent many of the current problems with the treatment of NO overproduction such as isoform selectivity. My PhD studies focus on the synthesis of a series of irreversible inhibitors of DDAH1, an extensive study of their in vitro mode of inhibition, a comparison of analytical fitting methods, and the viability and efficacy of the inactivators in a human cell line. I also studied a potential endogenous inactivator of DDAH1, nitroxyl (HNO), a one-electron reduction product of NO. / text

Exhaled breath condensate (EBC) is a non-invasive method of investigating airway inflammation associated with nitric oxide (NO) and the metabolites nitrite/nitrates (NOx) in diseases such as chronic obstructive pulmonary disease (COPD), but some of the variables affecting the results are unknown. It was hypothesised that 1) EBC would be influenced by lung volumes and the type of EBC collection device; 2) fractional exhaled NO (FENO) and EBC NOx in COPD patients would be altered by smoking and glucocorticosteroids (GCS); 3) cigarette smoke could contribute to the EBC NOx concentration while it may also decrease FENO indirectly by converting airway NO to NOx. It was found that EBC volume was significantly correlated with both tidal volume and minute volume. Comparing four EBC collection devices demonstrated greater efficiency with the ECoScreen?? than siliconised glass tubes or RTube?? but it gave factitiously high NOx levels. Total EBC protein levels over a 10-minute collection were significantly higher using the ECoScreen?? than either glass or RTube?? devices. A cross-sectional study of 96 COPD patients and 80 age-matched control subjects demonstrated that FENO levels in COPD patients were significantly higher than normal subjects when comparing either the combined groups or appropriate two subgroups: ex-smokers and smokers. GCS treatment demonstrated no significant effect on either FENO levels or EBC NOx, but EBC NOx was elevated in smokers. In vitro, cigarette smoke extract (CSE) induced significantly higher NOx and asymmetric dimethylarginine (ADMA) levels in A549 cells when compared with control media. The anti-oxidant, NAC pre-treatment partially reversed the elevated NOx levels but not the ADMA levels. This thesis is the first to report FENO and EBC NOx in COPD patients in an appropriate sample size to be able to evaluate each subgroup, and the increased EBC NOx levels found in smokers in vivo was consistent with the elevated NOx level in response to CSE observed in vitro. These data indicate that smoking-related airway inflammation and activation of the NO pathway are complex with both an increase in ADMA, NO, NOx and may be regulated by oxidative stress rather than the nitric oxide synthase (NOS) pathway.

No description available.